| Withdrawn | Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma NCT03613259 | OHSU Knight Cancer Institute | EARLY_Phase 1 |
| Unknown | Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma NCT04765228 | Yong Chen | Phase 2 |
| Completed | TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or NCT02180698 | Fred Hutchinson Cancer Center | Phase 1 |
| Withdrawn | NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid NCT02059850 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma NCT02048722 | Northwestern University | Phase 2 |
| Completed | A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas NCT01782313 | Northwestern University | Phase 2 |
| Completed | Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma NCT01719302 | University of Vermont | Phase 1 / Phase 2 |
| Completed | Biomarkers in Patients With Advanced Rhabdomyosarcoma NCT01668095 | Children's Oncology Group | — |
| Completed | Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery NCT01623869 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma NCT01446809 | University of Washington | N/A |
| Withdrawn | Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma NCT02507076 | Albert Einstein College of Medicine | N/A |
| Completed | Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Ca NCT01477021 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma NCT01462630 | Fox Chase Cancer Center | Phase 2 |
| Completed | Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent NCT01281865 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced NCT01206140 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced NCT01154452 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | 18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma NCT01169350 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue NCT01016015 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery NCT01553539 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma NCT00937495 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metasta NCT00720174 | National Cancer Institute (NCI) | Phase 1 |
| Completed | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma NCT00659360 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft NCT00346164 | Children's Oncology Group | Phase 3 |
| Completed | Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) NCT00330421 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma NCT00233948 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma NCT00245102 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma NCT00112463 | National Cancer Institute (NCI) | Phase 2 |
| Completed | CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor NCT00087074 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer NCT00087191 | National Cancer Institute (NCI) | N/A |
| Completed | Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma NCT00064324 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma NCT00003958 | Children's Oncology Group | Phase 3 |
| Terminated | EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer NCT00896961 | National Cancer Institute (NCI) | N/A |
| Terminated | BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma NCT00022542 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tiss NCT00019968 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Withdrawn | Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcom NCT00017160 | Radiation Therapy Oncology Group | Phase 2 |